Active substanceThymus extractThymus extract
Similar drugsTo uncover
  • Tactivin®
    solution PC 
  • Timalin®
    lyophilizate w / m 
    SAMSON-MED, LLC     Russia
  • Dosage form: & nbsphypodermic solution
    Composition:

    Active ingredient:

    Tactivine (thymus extract) - 0.1 mg; Auxiliary components: Sodium chloride - 8.85 mg;

    Water for injection up to 1 ml.

    Description:
    Colorless transparent liquid, odorless.

    Pharmacotherapeutic group:immunostimulating agent
    ATX: & nbsp

    L.03.A.X   Other immunostimulants

    Pharmacodynamics:
    It is an immunostimulating agent. In immunodeficient conditions, the drug normalizes the quantitative and functional indices of immunity, stimulates the production of lymphokines, including a- and y-interferon, restores the activity of T-killers, the functional activity of stem hemopoietic cells, and normalizes a number of other indices that characterize the intensity of immunity. Activates the macrophage system.

    Indications:
    • Applied in adults and children (from 6 months to 14 years) with immunodeficiency conditions arising when:
    • infectious purulent and septic processes;
    • lymphoproliferative diseases (lymphogranulomatosis, lymphocytic leukemia), lymphoproliferative diseases (lymphogranulomatosis, lymphocytic leukemia);
    • malignant neoplasms;
    • persistent violations of the function of the thymus (radiation sickness, tumors of the thymus, operative removal of the thymus);
    • Multiple sclerosis;
    • tuberculosis;
    • recurrent ophthalmoherpes;
    • psoriasis;
    • shingles;
    • dermatitis and dermatosis;
    • frequent recurring acute respiratory-viral diseases;
    • urological diseases of infectious etiology;
    • lung diseases (CHDF);
    • chronic viral hepatitis;
    • surgical interventions (in preoperative and postoperative periods);
    • thymomegaly.

    Contraindications:Pregnancy and lactation
    Dosing and Administration:
    Adults: subcutaneously, 1 ml of 0.01% solution (which is 40 mcg / m2 or 1-2 mcg / kg) is administered at night, once a day, daily for 5-14 days. If necessary, the course of treatment continues for 1 month to 2 ml every third day.
    With persistent impairments of immunity, Tactivine is prescribed for 5-14 days for 2 ml daily, and then 2 times a week for 2 ml for 6 months. Repeated courses of treatment are prescribed according to the indicators of immune status.
    With multiple sclerosis, the drug is used daily for 1 ml for 5 days, then 2 times a week for 2 ml for life.
    In severe cases of multiple sclerosis, Tactivine is prescribed in a complex therapy with glucocorticosteroids (at the stage of application of glucocorticosteroids once a day). Basis preparation is administered in the morning, and Tactivin in the evening time of 1 ml, observing the interval between the administration of glucocorticosteroids and Tactinol 10-12 hours.
    For the treatment of surgical patients Tactivine is administered before the operation for 1 ml for 2 days and after it - for 5-14 days.
    With malignant tumors, Tactivine is prescribed 5-6-day courses of 1 ml in intervals between courses of basic therapy.
    For the treatment of recurrent ophthalmoherpes, 0.1 ml of conjunctival drug is administered, which is 4 μg / m2 or 0.1-0.2 μg / kg / day at intervals of 1 day for 4-5 days, or 1 ml subcutaneously for 7-10 days.
    In herpes zoster inject 1 ml of Tactinone daily 7-10 days. The course of treatment can be repeated after 2-3 weeks.
    With hepatitis of various etiologies, Tactivine is prescribed for 2-3 ml daily for 10-12 days in combination with the basic preparations. The course of immunocorrection is repeated after 7 days.
    For children from 6 months to 14 years, the drug is administered subcutaneously at a rate of 2-3 μg per 1 kg of body weight.
    With frequent diseases of acute respiratory-viral diseases, purulent-septic infections, with atopic dermatitis complicated by herpesvirus, Tactivine is administered daily for 7-10 days in combination with the basic preparations. Subsequent administration of the drug for 1 to 2 weeks for 1 injection every other day.
    In malignant neoplasms and hepatitis in children, the treatment regimen does not differ from the treatment regimen in adults.
    It is recommended to enter in the evening between 17 and 20 hours.

    Side effects:Allergic reactions
    Form release / dosage:

    1 ml each preparation in ampoules of 1 ml or 2 ml containing 0.1 mg of tactotin.

    5 ampoules per circuit cell pack of film polyvinylchloride, sealed foil or without it. In a pack of cardboard box, one or two contour packagings with instructions for use are placed.

    In a pack of cardboard with a separating snake placed 5 or 10 ampoules with instructions for use.

    When using ampoules without a fracture ring or a break point, the ampoule scapper is additionally inserted into the pack.

    Packaging:

    5 ampoules per circuit cell pack of film polyvinylchloride, sealed foil or without it. In a pack of cardboard box, one or two contour packagings with instructions for use are placed.

    In a pack of cardboard with a separating snake placed 5 or 10 ampoules with instructions for use.

    When using ampoules without a fracture ring or a break point, the ampoule scapper is additionally inserted into the pack.

    Storage conditions:In the dark place at a temperature of 2-8 degrees.
    In a place inaccessible to children.
    Shelf life:3 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N003100 / 02
    Date of registration:05.11.2008
    The owner of the registration certificate:BIOMED them. I.I.Mechnikova, OJSC BIOMED them. I.I.Mechnikova, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp31.08.2015
    Illustrated instructions
      Instructions
      Up